Peer-Reviewed Publications:
Personalized Neoantigen Vaccine and Pembrolizumab in Advanced Hepatocellular Carcinoma: a Phase 1/2 Trial
Yarchoan M, Gane E, Marron T, Perales-Linares R, Yan J, Cooch N. Nature Medicine. 2024
A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation
Bhojnagarwala PS, Perales-Puchalt A, Cooch N, Sardesai NY and Weiner DB. Mol Ther Oncolytics. 2021
Neoantigen vaccines for cancer: ready for primetime
Perales-Puchalt A, Cooch N, Shende A, Sardesai NY. Immuno-Oncology Insights. 2020
Synthetic DNA multi-neoantigen vaccine drives predominately MHC class I CD8+ T cell mediated effector immunity impacting tumor challenge
Duperret EK, Perales-Puchalt A, Barlow J, Hiranjith GH, Chaudhuri A, Sardesai NY, Weiner DB Cancer Immunol Res. 2018.
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity
Walters JN, Ferraro B, Sardesai NY, Weiner DB, et al. Mol Ther. 2017.
Conference Posters:
Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Pembrolizumab as Second-Line Treatment for Advanced Hepatocellular Carcinoma
American Association for Cancer Research, 2024
Personalized immunization with GNOS-PV02 of patients with hepatocellular carcinoma drives TCR clonal expansion, tumor infiltration, and vaccine-specific reactivity.
American Society of Clinical Oncology (ASCO 2023).
Tracking MRD and neoantigen targets using a tumor-informed liquid biopsy platform in HCC patients treated with personalized cancer vaccine and pembrolizumab
American Society of Clinical Oncology (ASCO 2023).
Immune pressure in an advanced hepatocellular cancer patient following treatment with personalized neoantigen DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab).
Society for Immunotherapy of Cancer (SITC 2022).
Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen-targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab).
Society for Immunotherapy of Cancer (SITC 2022).
Personalized neoantigen DNA vaccines expand tumor-specific T cells in the periphery which infiltrate the tumor in hepatocellular carcinoma.
American Society of Clinical Oncology (ASCO 2022).
Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with pIL-12 and pembrolizumab for the treatment of patients with advanced HCC.
Society for Immunotherapy of Cancer (SITC 2021).
Personalized DNA vaccine in combination with plasmid-encoded IL-12 for the treatment of a patient with anaplastic astrocytoma.
Society for Immunotherapy of Cancer (SITC 2021).
Preclinical Analysis of novel synthetic DNA encoded multi-neoantigen targeting vaccine.
American Society of Gene & Cell Therapy (ASGCT 2020)